Jérôme Amiaud

ORCID: 0000-0003-3233-3793
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • TGF-β signaling in diseases
  • Bone Metabolism and Diseases
  • Heat shock proteins research
  • Sarcoma Diagnosis and Treatment
  • Mechanisms of cancer metastasis
  • Bone health and treatments
  • Cancer-related gene regulation
  • MicroRNA in disease regulation
  • Mesenchymal stem cell research
  • Cancer Research and Treatments
  • Glutathione Transferases and Polymorphisms
  • Cytokine Signaling Pathways and Interactions
  • Bone Tumor Diagnosis and Treatments
  • Sirtuins and Resveratrol in Medicine
  • Orthopedic Infections and Treatments
  • Molecular Biology Techniques and Applications
  • Immune cells in cancer
  • Ubiquitin and proteasome pathways
  • Orthopaedic implants and arthroplasty
  • Kruppel-like factors research
  • Rheumatoid Arthritis Research and Therapies
  • Bone fractures and treatments
  • Cancer-related molecular mechanisms research
  • Psoriasis: Treatment and Pathogenesis
  • Bone Tissue Engineering Materials

Nantes Université
2016-2025

Inserm
2016-2025

Centre National de la Recherche Scientifique
2022-2024

Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2022-2024

Université d'Angers
2023

École Pratique des Hautes Études
2021

La Ligue Contre le Cancer
2013-2016

Université Nantes Angers Le Mans
2015

Hôtel-Dieu de Paris
2014

IMT Atlantique
2013

Interleukin (IL)-36α, IL-36β and IL-36γ are expressed highly in skin involved the pathogenesis of psoriasis, while antagonists IL-36Ra or IL-38, another potential IL-36 inhibitor, limit uncontrolled inflammation. The expression role cytokines rheumatoid arthritis (RA) Crohn's disease (CD) is currently debated. Here, we observed that during imiquimod-induced mouse inflammation human IL-36α, γ IL-36Ra, but not IL-38 mRNA, was induced correlated with IL-1β T helper type 17 (Th17) (IL-17A,...

10.1111/cei.12761 article EN cc-by-nc Clinical & Experimental Immunology 2015-12-24

Interleukin‐34 (IL‐34) was recently characterized as the M‐CSF “twin” cytokine, regulating proliferation/differentiation/survival of myeloid cells. The implication in oncology initially suspected by reduced metastatic dissemination knock‐out mice, due to angiogenesis impairment. Based on this observation, our work studied involvement IL‐34 pathogenesis osteosarcoma. vivo effects were assessed tissue vasculature and macrophage infiltration a murine preclinical model based paratibial...

10.1002/ijc.29376 article EN International Journal of Cancer 2014-12-05

Objectives Interleukin (IL) 34 is a new cytokine implicated in macrophage differentiation and osteoclastogenesis. This study assessed IL-34 expression the tissue of patients with rheumatoid arthritis (RA). Methods Immunohistochemistry was performed synovial biopsies from RA (n=20), osteoarthritis (n=3) or other inflammatory (n=4). detected fluid by ELISA its messenger RNA studied quantitative PCR fibroblasts after stimulation tumour necrosis factor α (TNFα) IL-1β. Wild-type, jnk1 −/− –jnk2...

10.1136/annrheumdis-2011-200096 article EN Annals of the Rheumatic Diseases 2011-10-28

Human adipose tissue-derived stem cells (hATSC) have been contemplated as reparative for cartilage engineering. Chondrogenic differentiation of hATSC can be induced by an enriched culture medium and a three-dimensional environment. Given that bone is vascularized not, oxygen tension has suggested regulatory factor osteochondrogenic differentiation. Our work aimed at determining whether hypoxia affects the potential hATSC. were cultured in chondrogenic or osteogenic 28 days, pellets...

10.1152/ajpcell.00398.2009 article EN AJP Cell Physiology 2009-11-26

Dental pulp is a dynamic tissue able to resist external irritation during tooth decay by using immunocompetent cells involved in innate and adaptive responses. To better understand the immune response of toward gram-negative bacteria, we analyzed biological mediators rat incisor experimentally inflamed either lipopolysaccharide (LPS) or saline solution (phosphate-buffered [PBS]). Untreated teeth were used as control. Expression pro- anti-inflammatory cytokines, chemokine ligands, growth...

10.1177/0022034515612086 article EN Journal of Dental Research 2015-10-15

Repair of large bone defects remains a significant clinical challenge. Bone marrow stromal cells (BMSCs), subset which is known as marrow-derived mesenchymal stem cells, show therapeutic potential for regeneration. However, their isolation, expansion and implantation will need to be conducted under good manufacturing practices (GMP) at separate locations. An investigation mimics this scenario where shall regenerated required before trials can initiated. Seven batches 100 million human...

10.1186/scrt504 article EN cc-by Stem Cell Research & Therapy 2014-10-13

Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom prognosis remains poor, especially when metastasis present at diagnosis. Because transforming growth factor-β (TGFβ) has been shown to promote many solid tumors, we investigated effect of natural TGFβ/Smad signaling inhibitor Smad7 TβRI SD-208 on osteosarcoma behavior.By using a mouse model induced by paratibial injection cells, assessed impact overexpression or growth, microenvironment, remodeling,...

10.1158/1078-0432.ccr-13-3191 article EN Clinical Cancer Research 2014-08-09

Primary cancer cell dissemination is a key event during the metastatic cascade, but context-specific determinants of this process remain largely undefined. Multiple reports have suggested that p53 (TP53) family member p63 (TP63) plays an antimetastatic role through its minor epithelial isoform containing N-terminal transactivation domain (TAp63). However, and contribution major lacking domain, ΔNp63α, Here, we report distinct TAp63-independent mechanism by which ΔNp63α-expressing cells...

10.1158/0008-5472.can-15-2317 article EN Cancer Research 2016-03-18

// Camille Jacques 1, 2 , François Lamoureux Marc Baud'huin 2, 3 Lidia Rodriguez Calleja Thibaut Quillard Jérôme Amiaud Franck Tirode 4 Françoise Rédini James E. Bradner 5, 6 Dominique Heymann Benjamin Ory 1 INSERM, UMR 957, Équipe Labellisée Ligue 2012, Nantes, France Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université Nantes Atlantique Universités, EA3822, University Hospital, Institut Curie, INSERM U830, Paris, 5 Department of Medical...

10.18632/oncotarget.8214 article EN Oncotarget 2016-03-19

Oncostatin M (OSM) has been reported to be overexpressed in psoriasis skin lesions and exert proinflammatory effects vitro on human keratinocytes. Here, we report the role of OSM vivo a mouse model inflammation induced by intradermal injection murine OSM-encoding adenovirus (AdOSM) compare with that IL-6 injection. show potently regulates expression genes involved epidermal differentiation primary In vivo, AdOSM ears provoked robust thickening keratinocyte proliferation, while minimal effect...

10.1002/eji.201546216 article EN European Journal of Immunology 2016-04-28

Classically, particle-induced periprosthetic osteolysis at the implant–bone interface has explained aseptic loosening of joint replacement. This response is preceded by triggering both innate and acquired immune with subsequent activation osteoclasts, bone-resorbing cells. Although been considered a foreign body chronic inflammation mediated myelomonocytic-derived cells, current reports describe wide heterogeneous inflammatory cells infiltrating tissues. review aims to discuss role those...

10.3389/fimmu.2023.1310262 article EN cc-by Frontiers in Immunology 2023-12-01

Abstract Introduction Osteonecrosis of the femoral head (ONFH) is a degenerative disease progressing to (FH) collapse. Injection osteoprogenitor cells like bone marrow mesenchymal stromal (BMSCs) into FH appears be good therapeutic treatment. However, safety and efficacy BMSCs treat defect are main preclinical data required for clinical application. Efficacy lack risk cell transformation after amplification have been extensively described. The objectives this study were develop simple usable...

10.1186/s13287-015-0036-y article EN cc-by Stem Cell Research & Therapy 2015-04-10

// Audrey Lamora 1, 2, 3, 4 , Mathilde Mullard 3 Jérôme Amiaud Régis Brion Dominique Heymann Françoise Redini Franck Verrecchia 1 INSERM, UMR 957, Equipe Labellisée Ligue contre le Cancer 2012, Nantes, France 2 Université de Laboratoire Physiopathologie la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, CHU Hôtel Dieu, Inserm Liliane Bettencourt School, Correspondence to: Verrecchia, e-mail: franck.verrecchia@inserm.fr Keywords: halofuginone, osteosarcoma, TGF-β, metastases,...

10.18632/oncotarget.3891 article EN Oncotarget 2015-05-07

Background: Osteosarcoma is the most frequent form of malignant pediatric bone tumor. Despite current therapeutic arsenal, patient life-expectancy remains low if metastases are detected at time diagnosis, justifying research into better knowledge all stages osteosarcoma ontogenesis and identification new targets. Receptor Activator Nuclear factor κB (RANK)expression has been reported in cells, raising question Ligand (RANKL)/RANK signaling implications these tumor cells (intrinsic), addition...

10.3390/cancers10110398 article EN Cancers 2018-10-24

Bone destruction is a hallmark of chronic inflammation, and bone-resorbing osteoclasts arising under such condition differ from steady-state ones. However, osteoclast diversity remains poorly explored. Here, we combined transcriptomic profiling, differentiation assays in vivo analysis mouse to decipher specific traits for inflammatory osteoclasts. We identified validated the pattern-recognition receptors (PRR) Tlr2, Dectin-1, Mincle, all involved yeast recognition as major regulators showed...

10.7554/elife.82037 article EN public-domain eLife 2023-02-27

Rationale: During development, the contribution of IL34, a ligand macrophage colony stimulating factor receptor (MCSFR), has not been fully defined. Together with its twin cytokine MCSF, they display an essential role in differentiation and activation, including tissue specialized macrophages. The mechanism action each molecule involves phosphorylation MCSFR varying intensity kinetics. Furthermore, IL34 can interact other receptors cofactors, opening wide range modulations during...

10.7150/thno.107340 article EN cc-by Theranostics 2025-02-11

Osteosarcoma is medically defined as a bone-forming tumor with associated bone-degrading activity. There lack of knowledge about the network that generates overproduction bone. We studied early stage osteosarcoma development mice enduring periosteum injection cells at proximal third tibia. On day 7 (D7), activate over-synthesis bone-like material inside medulla. This bone quickly (D13) followed by degradation. Samples were characterized microfocus small-angle X-ray scattering (SAXS),...

10.3390/nano15050374 article EN cc-by Nanomaterials 2025-02-28

Osteosarcoma (OS) is the most common malignant bone tumor in children and teenagers. In many cases, such as poor response to treatment or presence of metastases at diagnosis, survival rate patients remains very low. Although literature, more studies are emerging on role Ubiquitin-Specific Proteases (USPs) development cancers, few data exist regarding OS. this context, RNA-sequencing analysis OS cells mesenchymal stem differentiated not into osteoblasts reveals increased expression four USPs...

10.3390/cells10092268 article EN cc-by Cells 2021-08-31

Abstract The development of osteosarcoma, the most common malignant primary bone tumor is characterized by a vicious cycle established between proliferation and paratumor osteolysis. This osteolysis mainly regulated receptor activator nuclear factor κB ligand (RANKL). Preclinical studies have demonstrated that Rankl blockade soluble receptors an effective strategy to prevent osteolytic lesions leading osteosarcoma inhibition. A new therapeutic option could be directly inhibit expression...

10.1002/jbmr.455 article EN Journal of Bone and Mineral Research 2011-06-28

Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges improving the response to chemotherapy warrants development new strategies improve overall patient survival. Among them, HSP90 is a molecular chaperone involved maturation and stability various oncogenic proteins leading tumor cells survival disease progression. We assessed antitumor properties synthetic inhibitor, PF4942847, alone or combination with zoledronic acid osteosarcoma.The effects PF4942847...

10.1158/1078-0432.ccr-15-1925 article EN Clinical Cancer Research 2015-12-29
Coming Soon ...